AUTHOR INDEX

(P = Proceedings)

AARUP A.-L. *see* GAIST D.
ABERG J. 24 h blood pressure monitoring and steady-state pharmacokinetics of felodipine metoprolol extended release tablet, 535P
AHERN D. *see* BALL S.E.
AHMED A. *see* TURNER C.L.
ALARAYYED N.A., COOPER M.B., PRICHARD B.N.C., BETTERIDGE D.J. & SMITH C.C.T. *In vitro* adrenaline and collagen induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine, 415
AL-SHAREEF A., BUSS D.C., SHETTY H.G.M., ALI N. & ROUTLEDGE P.A. The effect of activated dose renal charcoal on the pharmacokinetics of sodium valproate in healthy volunteers, 109
ALI N. *see* AL-SHAREEF A.
ALLAIN H. *see* PATAT A.
ALURI J. *see* BEERAHEE A.
ALVAN G. *see* SANDWALL P.
ALVAN G. *see* WAKELKAMP M.
AMAMOTO T. *see* IEIRI I.
ANDERSON M. *see* GAIST D.
ANDERSSON S. *see* RANE A.
ANGELINI G.D. *see* LEWIS C.
AOYAMA K., UCHIDA T., TAKANUKI F., WATANABE T., HIGUCHI S., TOYOKI T. & MIZOGUCHI H. Pharmacokinetics of recombinant interleukin-11 (rhIL-11) in healthy male subjects, 571
ARBEENY C. *see* CLARK D.J.
ARCHER C.B. *see* SABROE R.A.
ASHTON C.H. *see* KAMALI F.
ASTBURY S., YOGENDRAN L. & JULIOUS S. Reproducibility of elbow width measurement used in the assessment of body frame size in Metropolitan Life Tables, 534P
AVENOSO A. *see* SPINA E.

BAAN J., CHANG P.C., VERMEIJ P., PFAFFERNDORF M. & VAN ZWIETEN P.A. Venous constrictor responses to angiotensin II in the human forearm vascular bed, 526P
BACK D.J. *see* BARRY M.
BACK D.J. *see* TOMLINSON E.S.
BACK D.J., McINNES G.T. & TUCKER G.T. Editorial. New cover—renewed commitment, 1
BAIGENT A. The need for large-scale randomized evidence, 349
BAILEY R.R. *see* SAUNDERS D.A.
BALL S.E., AHERN D., SCATINA J. & KAO J. Venlafaxine: *in vitro* inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2, 619
BAMBER R.W.K. *see* VILE J.M.
BANDERA M. *see* SLEE D.
BANOUB A. *see* NIGROVIC V.
BARCLAY P. *see* SPICER S.T.
BARDSTREET T. *see* SCIBERRAS D.G.
BARNES P.J. Book review. Potassium channels and their modulators edited by J.M. Evans, T.C. Hamilton, S.D. Longman & G. Stemp, 123
BARNES S.V. *see* KENNA J.G.
BARRY M., MERRY C., MULCAHY F., HEAVEY J., TJIA J., GIBBONS S. & BACK D.J. Saquinavar pharmacokinetics alone and in combination with ritonavir, 531P
BATEMAN D.N. *see* THOMAS S.H.L.
BATTY G.M. *see* OBORNE C.A.
BAXTER T. & EADIE C.J. Twenty-four hour plasma profile of sustained-relase isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials, 333
BEAUNE P. *see* KENNA J.C.
BEERAHEE A., NICHOLS A.I., ALURI J., DARWISH M., McCORMACK P., CITERONE D., MILLER A., TAYLOR A.C. & KREIDER M. Population pharmacokinetics of ropinirole in patients with Parkinson's disease, 556P
BEGAUD B. *see* MORIDE Y.
BEGG E.J. *see* DUFFULL S.B.
BEGG E.J. *see* SAUNDERS D.A.
BEHAR A., PUJADE-LAURAINE E., MAUREL A., BRUN M.D., LAGRUE G., FEUILHADE DE CHAUVIN F., OULID-AISSA D. & HILLE D. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication, 653
BENJAMIN N. *see* LYONS D.
BENNETT T. *see* NOON J.P.
BENOWITZ N.L., ZEVIN S. & JACOB P. III Sources of variability in nicotine and cotinine levels with use of nicotine, and cigarette smoking, 259
BERGSTROM M. *see* LUNELL E.
BERLIN I., RADAT F., SPREUX-VAROQUAX O. & PEUCH A.J. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression, 532P
BERTOCCHI M. *see* BOULIEU R.
BETTERIDGE D.J. *see* ALARAYYED N.A.
BETTIGA A. *see* WILDER-SMITH C.H.
BEVIS P.J.R. *see* BOULTON-JONES J.M.
BHABRA M.J. *see* PETIT M.J.
BIRKETT D.J. *see* ZHANG H.
BIRKETT D.J., MINERS J.O., VALENTE L., LILLYWHITE K.J. & DAY R.O. 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect, 197
BIRNIE D. *see* HOOD S.
BITSIOS P., LANGLEY R.W., TAVERNOR S., SZABADI E. & BRADSHAW C.M. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man, 551P
BJELFMAN C. *see* FINNSTROM N.
BJELFMAN C. *see* RANE A.
BLACK P. *see* BOATH E.
BLAKE J.A.R. *see* PRITCHARD M.P.
BLIGH J. *see* LLOYD-JONES G.
BLOUIN R.A. *see* SHEDLOFSKY S.I.
BLUMBERG J. *see* LAMRANI A.
BOATH E., MUCKLOW J. & BLACK P. Consulting the oracle: a Delphi Study to determine the content of a postgraduate distance learning course in therapeutics, 643
BOCHNER F. *see* COLLER J.K.
BOIKE S.C. *see* MARTIN D.E.
BONDE J. *see* OLSEN N.V.
BOOBIS A.R. *see* PENG S.-W.
BOON N.A. *see* NEWBY D.E.
BOULIEU R., LENOIR A., BERTOCCHI M. & MORNEX J-F. Intracellular thiopurine nucleotides and azathioprine myelotoxicity in organ transplant patients, 116
BOULTON-JONES J.M., GEDDES C.G., HEINZEL G., TURCK D., NEHMIZ G. & BEVIS P.J.R. Meloxicam pharmacokinetics in renal impairment, 35
BOWMAN A.J. *see* SCIBERRAS D.G.
BRADSHAW C.M. *see* BITSIOS P.
BREKKAN E. *see* RANE A.
BRETIENDER H. *see* KREJCY K.
BRETT S.E., COCKCROFT J.R., MATZ J., MANT T.G.K., RITTER J.M. & CHOWIENCZYK P.J. Effects of nitric oxide synthase inhibition and L-arginine on exercise haemodynamics, 528P
BRIXIUS K. *see* MULLER-EHMSEN J.
BRODDE O.-E. *see* POLLER U.D.
BROOKS C.D. *see* DALEY-YATES P.T.
BRØSEN K. *see* BUUR RASMUSSEN B.
BROWN A. *see* FALCOZ C.
BROWN M.J. *see* FERRO A.
BRUN M.D. *see* BEHAR A.
BRUNE K. *see* OELKERS R.
BUCHANAN K.D. *see* McDOWELL G.
BURCHELL B. *see* PRITCHARD M.P.
BURGGRAAF J.A *see* FAAIJ R.A.
BUSS D.C. *see* AL-SHAREEF A.
BUSS D.C., MARSHALL R.W., MILLIGAN N., McQUEEN I., COMPSTON D.A.S. & ROUTLEDGE P.A. The effect of intravenous aminophylline on essential tremor, 119
BUUR RASMUSSEN B. & BRØSEN K. Theophylline has no advantages over

© 1997 Blackwell Science Ltd

caffeine as a putative model drug for assessing CYP1A2 activity in humans, 253
BUZELLO W. *see* NIGROVIC V.
BYE A. *see* MACKIE A.E.

CALDWELL J. *see* SOMCHIT N.
CAMPO G.M. *see* SPINA E.
CAMPOS A. *see* SEMPERE J.M.
CAPUTI A.P. *see* SPINA E.
CARGILL R.I. *see* KIELY D.G.
CARRUPT P.-A. *see* CHEYMOL G.
CARTER K.C. *see* MULLEN A.B.
CARVALHO M. *see* FEELY J.
CATUS F. *see* LAMRANI A.
CHAN D.T.M. *see* LO A.C.Y.
CHANG P.C. *see* BAAN J.
CHAPMAN J.R. *see* SPICER S.T.
CHARLETT A. *see* PURKISS A.G.
CHARLETT A., PURKISS A.G., PETERSON D.W., WELLER C., DOBBS R.J. & DOBBS S.M. Effect of age and facets of idiopathic parkinsonism on serum concentrations of tumour necrosis factor-α, 553P
CHAUSSADE S. *see* LAMRANI A.
CHENG H. *see* SCIBERRAS D.G.
CHENG I.K.P. *see* LO A.C.Y.
CHEYMOL G., POIRIER J.-M., CARRUPT P.-A., TESTA B., WEISSENBURGER J., LEVRON J-C. & SNOECK E. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers, 563
CHITTICK G. *see* SEABER E.
CHOONARA I. *see* PARKER A.C.
CHOWIENCZYK P.J. *see* BRETT S.E.
CHRYSTYN H. *see* HINDLE M.
CIMAROSTI I. *see* PATAT A.
CITERONE D. *see* BEERAHEE A.
CITERONE D. *see* MARTIN D.E.
CITERONE D.R. *see* TAYLOR A.C.
CLARK D.J. & LIPWORTH B.J. Evaluation of corticotrophin releasing factor stimulation and basal markers of HPA-axis suppression in asthmatic patients, 206P
CLARK D.J. & LIPWORTH B.J. Lung absorption of salbutamol given by dry powder inhaler and small antistatic metal spacer, 530P
CLARK D.J. & LIPWORTH B.J. Lung bioavailability of salbutamol given by breath-activated pressurized aerosol and dry powder inhaler devices, 542P
CLARK D.J., ARBEENY C. & LIPWORTH B.J. Extrapulmonary β_2-adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers, 529P
CLAYTON R. *see* SCIBERRAS D.G.
CLEOPHAS T.J.M., V.D. MEULEN J. & KALMANSON R.B. Clinical trials: specific problems associated with the use of a placebo control group, 219
COCKCROFT J.R. *see* BRETT S.E.
COCKCROFT J.R. *see* NOON J.P.
COHEN A.F. *see* FAAIJ R.A.
COLEMAN R.A. *see* WEERSINK E.J.M.
COLLER J.K., SOMOGYI A.A. & BOCHNER F. Association between CYP2C19 genotype and proguanil oxidative polymorphism, 659
COLVILLE P.F. Evidence for the involvement of human CYP3A in the 3-hydroxylation of quinine, 245
COLVILLE P.F. *see* ZHANG H.
COMPSTON D.A.S. *see* BUSS D.C.
CONGPUONG K. *see* NA-BANGCHANG
COOKE T. *see* WEN Y.
COOPER J.D.H. *see* WOOTTON R.
COOPER M.B. *see* ALARAYYED N.A.
COOPER S. *see* TAYLOR A.C.
CORDATO D.J., GROSS A.S., HERKES G.K. & MATHER L.E. Pharmacokinetics of thiopentone enantiomers follwing intravenous injection or prolonged infusion of *rac*-thiopentone, 355
COSTELLO J.F. *see* CROWTHER S.D.
COUTIE W. *see* McDOWELL G.
COX J. *see* KAMALI F.
CROWTHER S.D., C.P., COSTELLO J.F., KILFEATHER S. & MORLEY J. Aerosols of bradykinin do not cause retrosternal chest discomfort and rarely evoke cough in mild asthmatics, 542P
CYRONAK M. *see* TAYLOR A.C.

DAHLEN P. *see* SANDWALL P.
DAHLSTROM K. *see* THORSSON L.
DALEY-YATES P.T. *see* PARKER T.J.
DALEY-YATES P.T., GREGORY A.J. & BROOKS C.D. Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone, 593
DALZELL A.M. *see* PARKER A.C.
DANHOF M. *see* SNOECK E.
DARWISH M. *see* BEERAHEE A.
DAVIS T.M.E. Letter to the Editor. Reply: neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial, 665
DAY R.O. *see* BIRKETT D.J.
DE ALMEIDA PIEROSSI M. *see* PEDRAZZOLI JUNIOR J.
DE NUCCI G. *see* PEDRAZZOLI JUNIOR J.
DE WAZIERS I. *see* KENNA J.C.
DEYBACJ J.C. *see* RICHENS A.
DIAS H.B. *see* PEDRAZZOLI JUNIOR J.
DIAZ J. *see* SEMPERE J.M.
DICKERSON J.E.C. *see* FERRO A.
DIEFENBACH C. *see* NIGROVIC V.
DINGEMANSE J., WOOD N., JORGA K. & KETTLER R. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazebemide in healthy subjects, 41
DIXON R., GILLOTIN C., GIBBENS M., POSNER J. & PECK R.W. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers, 273
DIXON R.M. *see* SEABER E.
DOBBS R.J. *see* CHARLETT A.
DOBBS R.J. *see* PURKISS A.G.
DOBBS S.M. *see* CHARLETT A.
DOBBS S.M. *see* PURKISS A.G.
DONNELLY N. *see* VILE J.M.
DOYLE M.C.T. *see* WEN Y.
DRUMMOND M. *see* HAYCOX A.
DUARTE MENDES F. *see* PEDRAZZOLI JUNIOR J.
DUCHARME J., FRIED K., SHEMOUDA G., LEYLAND-JONES B. & WAINER I.W. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen, 189
DUFFULL S.B., KIRKPATRICK C.M.J. & BEGG E.J. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens, 125
DUPONT A.G. *see* SNOECK E.
DURRIEU G. *see* PATAT A.

EADIE C.J. *see* BAXTER T.
EAGLES C.J. & KENDALL M.J. The effects of combined treatment with β_1-selective antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects, 291
EDSBACKER S. *see* THORSSON L.
EDWARDS M. *see* SCIBERRAS D.G.
EDWARDS R.J. *see* PENG S.-W.
EICHLER H-G. *see* KREJCY K.
ELIASSON E. *see* KENNA J.C.
ELLIS S.E. *see* GHAHRAMANI P.
ERNST P. & SUISSA S. Letter to the Editor. The asthma death problem revisited, 339
EVANS S.J.W. & WALLER P.C. Letter to the Editor. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial, 665

FAAIJ R.A., SRIVASTAVA N., VAN GRIENSVEN J.M.TH., SCHOEMAKER R.C., KLUFT C., BURGGRAAF J.A & COHEN A.F. The oral bioavailability of pentosan polysulphate sodium (PPS) in healthy volunteers, 556P
FALCOZ C. *see* MACKIE A.E.
FALCOZ C., MACKIE A.E., HORTON J., BROWN A., FIELD E., HARDING S.M. & WIRE P. Pharmacokinetics of fluticasone proprionate inhaled from the Diskhaler® and the Diskus® powder devices in asthmatic patients, 541P
FEELY J. *see* HEMERYCK K.
FEELY J. *see* McGETTIGAN P.
FEELY J. *see* WEN Y.
FEELY J., CARVALHO M., KELLY M., KILLALEA S., HALL M., McGOVERN E. & McGETTIGAN P. Lipid-lowering drugs: are we treating the appropriate population? 206
FERREIRA DA SILCA C.M. *see* PEDRAZZOLI JUNIOR J.
FERRO A., HALL J.A., DICKERSON

J.E.C. & BROWN M.J. A prospective study of the effects of prolonged timolol therapy on α- and β-adrenoceptor and angiotensin II receptor mediated responses in normal subjects, 301
FEUILHADE DE CHAUVIN F. *see* BEHAR A.
FIELD E. *see* FALCOZ C.
FINNSTROM N. *see* PENG S.-W.
FINNSTROM N., THON M., BJELFMAN C., LOOF L. & RANE A. Quantitative assessment of cytochrome P450 mRNAs in liver needle biopsies, 217P
FITZKE F.W. *see* VILE J.M.
FITZPATRICK K. *see* TAYLOR A.C.
FOOK SHEUNG C.T.C. *see* WOOTTON R.
FORD G.A. *see* KAMALI F.
FORD G.A. *see* SCIBERRAS D.G.
FORSLING M.L. *see* KOSTOGLOU-ATHANASSIOU I.
FORSLING M.L. *see* SHARMA S.
FORSTER E.R. *see* PALMER J.L.
FOWLER P.A. *see* KELLY T.B.
FRANK K. *see* MULLER-EHMSEN J.
FRENG-GRAM L. *see* GAIST D.
FRIED K. *see* DUCHARME J.
FRIEDBERG T. *see* PRITCHARD M.P.
FRIEDBERG T. *see* SLEE D.
FUCHS B. *see* POLLER U.D.
FURTEK C. *see* SANDWALL P.

GAIST D., ANDERSON M., AARUP A.-L., HALLAS J. & FRENG-GRAM L. Use of sumatriptan in Denmark in 1994–5: an epidemiological analysis of nationwide prescription data, 429
GANDON J.M. *see* PATAT A.
GARCIA-RODRIGUEZ L.A., WALLANDER M-A. & STRICKER B.H. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs, 183
GARDNER I. *see* KENNA J.C.
GARDNER I.B. *see* SOMCHIT N.
GARDNER-MEDWIN J.M., TAYLOR J.Y., MACDONALD I.A. & POWELL R.J. An investigation into variability in microvascular skin blood flow and the responses to transdermal delivery of acetylcholine at different sites in the forearm and hand, 391
GARLAND C.J. *see* LEWIS C.
GAZZARD B.G. *see* NOORMOHAMED F.H.
GEDDES C.G. *see* BOULTON-JONES J.M.
GEISSLINGER G. *see* OELKERS R.
GEJMAN P.V. *see* POHJALAINEN T.
GERTZ B.J. *see* NEWBY D.E.
GERTZ B.J. *see* SCIBERRAS D.G.
GHAHRAMANI P., ELLIS S.E., LENNARD M.S., L.E. RAMSAY & TUCKER G.T. Cytochromes P450 mediating the *N*-methylation of amitriptyline, 137
GHARAMANI P., ROWLAND-YEO K., YEO W.W., JACKSON P.R. & RAMSAY L.E. A new *in vitro* method for measuring protein binding of drugs, 207P
GIBBENS M. *see* DIXON R.
GIBBENS M. *see* SEABER E.
GIBBONS S. *see* BARRY M.
GILHAM D.E The metabolism of MPTP by CYP2D6 and the demonstration of CYP2D6 mRNA in human brain *in situ* hybridization, 210P
GILLOTIN C. *see* DIXON R.
GOLDBERG M.R. *see* SCIBERRAS D.G.
GOLDING J.F. & STOTT R.R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate, 633
GORCHEIN A. Letter to the Editor. Drug treatment of hypertension in acute intermittent porphyria: doxazsoin and amlodipine, 339
GRAHAM G.G. *see* SAUNDERS D.A.
GRANT M.H. *see* MULLEN A.B.
GRANT M.H. *see* TETTEY J.
GREEN J.F. & KING D.J. Abnormal saccadic distractibility and effects of antisaccade task subcomponents in human subjects in response to single doses of chlorpromazine and lorazepam, 532P
GREGORY A.J. *see* DALEY-YATES P.T.
GROSS A.S. *see* CORDATO D.J.
GROVE A. *see* LIPWORTH B.J.

HALL J.A. *see* FERRO A.
HALL M. *see* FEELY J.
HALL M. *see* WEN Y.
HALLAS J. *see* GAIST D.
HANRATTY C. *see* McAULEY D.
HARAMBARU F. *see* MORIDE Y.
HARDER S. & THURMANN P.A. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers, 475
HARDING S.M. *see* FALCOZ C.
HARRISON R.F. *see* WEN Y.
HAYCOX A. & WALLEY T. Pharmacoeconomics: evaluating the evaluators, 451
HAYCOX A. *see* WALLEY T.
HAYCOX A., DRUMMOND M. & WALLEY T. Pharmacoeconomics: integrating economic evaluation into clinical trials, 559
HEAVEY J. *see* BARRY M.
HEINZEL G. *see* BOULTON-JONES J.M.
HEMERYCK K., McGETTIGAN P. & FEELY J. Hospital antibiotic prescribing and feedback, 449
HEMERYCK L. *see* WEN Y.
HERKES G.K. *see* CORDATO D.J.
HEYKANTS J. *see* SNOECK E.
HIETALA J. *see* POHJALAINEN T.
HIGGS C.J. *see* NOORMOHAMED F.H.
HIGUCHI S. *see* AOYAMA K.
HIGUCHI S. *see* IEIRI I.
HILLE D. *see* BEHAR A.
HILLIS S. *see* HOOD S.
HINDLE M., PEERS E.M., PARRY-BILLINGS M. & CHRYSTYN H. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler, 336
HOOD S., BIRNIE D. & HILLIS S. The haemodynamic effects of subcutaneous sumatriptan, a $5HT_1$-receptor agonist, 327
HORTON J. *see* FALCOZ C.
HOWBROOK D.N. *see* SLEE D.
HOWES A. *see* KAMALI F.
HUME-SMITH H.V. *see* KENNA J.C.
HUSSEIN Z. & POSNER J. Population pharmacokinetics of lamogotrine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data, 457

IEIRI I., MAMIYA K., URAE A., WADA Y., KIMURA M., IRIE S., AMAMOTO T., KUBOTA T., YOSHIOKA S., NAKAMURA K., NAKANO S., TASHIRO N. & HIGUCHI S. Stereoselecetive 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese, 441
IKEDA Y. *see* UMEMURA K.
ILSON B. *see* MARTIN D.E.
IRIE S. *see* IEIRI I.
ISRAEL B.C. *see* SHEDLOFSKY S.I.

JACKSON P.R. *see* GHARAMANI P.
JACKSON S.H.D. *see* OBORNE C.A.
JACOB P. III *see* BENOWITZ N.L.
JANE D.E. Book review. Advanced drug design and development: a medicinal chemistry approach edited by P.N. Kourounakis, 123
JARRTI T., KAILA T., TAHVANAINEN K., KUUSELA T., VANTO T. & VALIMAKI I. The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis, 421
JICK H. *see* WALD MEYERS M.
JOHNSTON G.D. *see* McAULEY D.
JOHNSTON G.D. *see* McGURK C.
JOHNSTON G.D. *see* NUGENT A.G.
JONES M. *see* PETIT M.J.
JONES R.W. *see* TURNER C.L.
JONSSON A. *see* RYDBERG T.
JONZON B. *see* SANDWALL P.
JORGA K. *see* DINGEMANSE J.
JORKASKY D.K. *see* MARTIN D.E.
JOYCE D.A. *see* STEER J.H.
JULIOUS S. *see* ASTBURY S.

KAILA T. *see* JARRTI T.
KALLEN A. *see* THORSSON L.
KALMANSON R.B. *see* CLEOPHAS T.J.M.
KAMALI F., ASHTON C.H., MARSH V.R. & COX J. Is there a pharmacodynamic interaction between ciprofloxacin and fenbufen? 545P
KAMALI F., HOWES A., THOMAS S.H.L., FORD G.A. & SNOECK E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and

the H_2-receptor antagonists cimetidine and ranitidine, 201
KANSTRUP I-L. *see* OLSEN N.V.
KANTOLA T. *see* VILLIKKA K.
KAO J. *see* BALL S.E.
KARBWANG J. *see* NA-BANGCHANG
KARLSSON M.O. *see* RYDBERG T.
KASKI J.C. *see* KNOTT C.
KELLY M. *see* FEELY J.
KELLY T.B., FOWLER P.A. & THOMAS M. Protocol evaluation: a review of Glaxo in-house protocols between 1973 and 1995, 533P
KENDALL M.J. *see* EAGLES C.J.
KENNA J.C., HUME-SMITH H.V., GARDNER I., DE WAZIERS I., BEAUNE P. & ELIASSON E. Formation of the CE3-Co-protein antigens implicated in the pathogenesis of halothane hepatitis is catalysed in human liver microsomes *in vitro* by CYP 2E1, 209
KENNA J.G. *see* SOMCHIT N.
KENNA J.G., BARNES S.V. & ELIASSON E. An immunoprecipitation technique for detection of antibodies to novel drug-induced hepatic antigens, 208
KENNEDY C.T.C. *see* SABROE R.A.
KETTLER R. *see* DINGEMANSE J.
KIELY D.G., CARGILL R.I. & LIPWORTH B.J. Effects of frusemide and hypoxia on the pulmonary vascular bed in man, 309
KILFEATHER S. *see* CROWTHER S.D.
KILLALEA S. *see* FEELY J.
KILLALEA S. *see* WEN Y.
KIM R.B. *see* O'SHEA D.
KIMURA M. *see* IEIRI I.
KIMURA M. *see* KOSUGE K.
KING D.J. *see* GREEN J.F.
KINGSWOOD J.C. *see* PETIT M.J.
KIRKPATRICK C.M.J. *see* DUFFULL S.B.
KIRKPATRICK C.M.J. *see* SAUNDERS D.A.
KITTERINGHAM N.R. *see* POWELL H.
KIVISTO K.T. *see* LAINE K.
KIVISTO K.T. *see* VILLIKKA K.
KLUFT C. *see* FAAIJ R.A.
KNOTT C., SHAH D., TIPPINS J.R., WILKIN J.P., KASKI J.C., MADDEN B. & MURDAY A. Regional distribution of glutathione transferase π immunoreactivity in human coronary arteries, 213P
KOETER G.H. *see* WEERSINK E.J.M.
KONDO K. *see* UMEMURA K.
KOSTOGLOU-ATHANASSIOU I., TREACHER D.F., WHEELER M.J. & FORSLING M.L. The effect of exogenous melatonin on cortisol, prolactin and growth hormone secretion in man, 543P
KOSUGE K., NISHIMOTO M., KIMURA M., UMEMURA K., NAKASHIMA M. & OHASHI K. Enhanced effect of triazolam with diltiazem, 367
KREIDER M. *see* BEERAHEE A.
KREJCY K., WOLTZT M., KREUZER C., BRETIENDER H., SCHUTZ W., EICHLER H-G. & SCHMETTERER L. Characterization of angitensin-II effects on cerebral and ocular circulation by non-invasive methods, 501
KREUZER C. *see* KREJCY K.
KUBOTA T. *see* IEIRI I.
KUUSELA T. *see* JARRTI T.

LAAKSO I. *see* LAINE K.
LAER S., NEUMANN J. & SCHOLZ H. Interaction between sotalol and an antacid preparation, 269
LAGRUE G. *see* BEHAR A.
LAINE K., KIVISTO K.T., LAAKSO I. & NEUVONEN P.J. Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration, 29
LAMBERG T.S. *see* VILLIKKA K.
LAMRANI A., VIDON N., SOGNI P., NEPVEUX P., CATUS F., BLUMBERG J. & CHAUSSADE S. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans, 65
LANGLEY R.W. *see* BITSIOS P.
LANGSTROM B. *see* LUNELL E.
LANT A.F. *see* NOORMOHAMED F.H.
LEAVENS W.J. *see* SEABER E.
LEE A.F.C., McFARLANE L.C. & STRUTHERS A.D. Acute dosing with female sex hormones does not alter vascular angiotensin converting enzyme activity or fasted lipids in male volunteers, 212P
LEENAN F.H.H. *see* WHITE M.
LEFEBVRE R.A., VAN PEER A. & WOESTENBORGHS R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole, 319
LENNARD L., MORTON G.C.A., WELCH J. & LILLEYMAN J.S. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentration after an oral dose, 544P
LENNARD M.S. *see* GHAHRAMANI P.
LENNARD M.S. *see* ROSTAMI-HODJEGAN A.
LENOIR A. *see* BOULIEU R.
LEVRON J-C. *see* CHEYMOL G.
LEWIS C., GARLAND C.J., ANGELINI G.D. & PLANE F. Contractile function is reduced in surgically-prepared human saphenous vein, 537P
LEWIS D.F.V. *see* TOMLINSON E.S.
LEYLAND-JONES B. *see* DUCHARME J.
LEYSSAC P.P. *see* OLSEN N.V.
LIDDLE C. *see* SPICER S.T.
LILLEYMAN J.S. *see* LENNARD L.
LILLYWHITE K.J. *see* BIRKETT D.J.
LIND M. *see* SANDWALL P.
LIPWORTH B.J. & GROVE A. Evaluation of partial β-adrenoceptor agonist activity, 9
LIPWORTH B.J. *see* CLARK D.J.
LIPWORTH B.J. *see* KIELY D.G.
LLOYD-JONES G., WALLEY T. & BLIGH J. Integrating clinical pharmacology in a new problem based medical undergraduate curriculum, 15
LO A.C.Y., LUI S-L., LO W-K., CHAN D.T.M. & CHENG I.K.P. Letter to the Editor. The interaction of terbinafine and cyclosporine A in renal transplant patients, 341
LO M-W. *see* SANDWALL P.
LO W-K. *see* LO A.C.Y.
LOGAN C.J. *see* SLEE D.
LOOF L. *see* FINNSTROM N.
LOPEZ-GILL A. *see* TAYLOR A.C.
LUI S-L. *see* LO A.C.Y.
LUNELL E., BERGSTROM M. & LANGSTROM B. Regional deposition in the human airways of inhaled [^{11}C]-nictotine vapour and cigarette smoke and body distribution of [^{11}C]-nicotine visualized by positron emission tomography (PET), 206P
LYONS D., WEBSTER J., NIXON A., YOUNG M.M.R., SMITH J. & BENJAMIN N. Effect of non peptide angiotensin II antagonist, GR117289C on the vasoconstrictor actions of angiotensin II in the human forearm, 323

MACDONALD I.A. *see* GARDNER-MEDWIN J.M.
MACKIE A.E. *see* FALCOZ C.
MACKIE A.E., FALCOZ C., McDOWALL J.E., MOSS J., VENTRESCA G.P. & BYE A. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in healthy subjects, 540P
MADDEN B. *see* KNOTT C.
MAGGS J.L. *see* TOMLINSON E.S.
MAGREN K. *see* POHJALAINEN T.
MAGUIRE S. *see* McAULEY D.
MAGUIRE S. *see* McGURK C.
MAGUIRE S. *see* NUGENT A.G.
MAJMUDAR N. *see* SCIBERRAS D.G.
MAMIYA K. *see* IEIRI I.
MAN Y. *see* WEERSINK E.J.M.
MANSON S.M. *see* MORDI M.N.
MANT T. *see* SCIBERRAS D.G.
MANT T.G.K. *see* BRETT S.E.
MARSH V.R. *see* KAMALI F.
MARSHALL R.W. *see* BUSS D.C.
MARTIN D.E., TOMPSON D., BOIKE S.C., TENERO D., ILSON B., CITERONE D. & JORKASKY D.K. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers, 661
MASKREY V. *see* OBORNE C.A.
MASSEY A. *see* SCIBERRAS D.G.
MATHER L.E. *see* CORDATO D.J.
MATTILA M.J. & MATTILA-EVENDEN M.E. Peculiarities in the digit symbol substitution tests, 214P
MATTILA-EVENDEN M.E. *see* MATTILA M.J.

MATZ J. *see* BRETT S.E.
MAUREL A. *see* BEHAR A.
McAULEY D. *see* McGURK C.
McAULEY D. *see* NUGENT A.G.
McAULEY D., McGURK C., NUGENT A.G., HANRATTY C., MAGUIRE S. & JOHNSTON G.D. The effect of cyclooxygenase inhibition on forearm vascular responses to endothelin-1 in healthy volunteers, 540P
McAULEY D., McGURK C., NUGENT A.G., HANRATTY C., MAGUIRE S. & JOHNSTON G.D. The role of the potassium-ATP channel in forearm endothelial-dependent vascular responses, 537P
McAULEY D., McGURK C., NUGENT A.G., MAGUIRE S., HANRATTY C. & JOHNSTON G.D. The effect of cyclooxygenase inhibition on forearm vascular responses to endothelin-1 in patients with NIDDM, 539P
McCOLL K.E.L. *see* PENSTON J.G.
McCORMACK P. *see* BEERAHEE A.
McCREA J. *see* SANDWALL P.
McDONALD J. *see* SHINE D.
McDOWALL J.E. *see* MACKIE A.E.
McDOWELL G., COUTIE W., SHAW C., BUCHANAN K.D., STRUTHERS A.D. & NICHOLLS D.P. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides, 329
McEWAN J.R. *see* RICHENS A.
McFARLANE L.C. *see* LEE A.F.C.
McGETTIGAN P. & FEELY J. Audit of hospital prescribing: gulf between indication and therapy, 556P
McGETTIGAN P. *see* FEELY J.
McGETTIGAN P. *see* HEMERYCK K.
McGETTIGAN P. *see* WEN Y.
McGOVERN E. *see* FEELY J.
McGURK C. *see* McAULEY D.
McGURK C. *see* NUGENT A.G.
McGURK C., McAULEY D., NUGENT A.G., MAGUIRE S. & JOHNSTON G.D. Impaired endothelial dependent responses, without impaired basal or stimulated nitric oxide production, in the forearm vasculature of non-insulin dependent diabetics, 538P
McINNES G.T. *see* BACK D.J.
McKINNELL I. *see* VILE J.M.
McQUEEN I. *see* BUSS D.C.
MELANDER A. *see* RYDBERG T.
MELLINGHOFF H. *see* NIGROVIC V.
MENDEL C.M. *see* NEWBY D.E.
MERLO J. & RANSTAM J. Ocular safety of anti-ulcer drugs, 449
MERRY C. *see* BARRY M.
MICHEL M.C. *see* TAGUCHI K.
MIDGLEY J.M. *see* TETTEY J.
MILLER A. *see* BEERAHEE A.
MILLIGAN N. *see* BUSS D.C.
MINERS J. *see* O'CALLAGHAN G.
MINERS J.O. *see* BIRKETT D.J.
MINERS J.O. *see* ZHANG H.
MITCHELL C. *see* PALMER J.L.
MIZOGUCHI H. *see* AOYAMA K.
MORDI M.N., MANSON S.M., NAVARATNAM V. & WERNSDORFER W.H. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers, 363
MORIDE Y., HARAMBARU F., REQUEJO A.A. & BEGAUD B. Under-reporting of adverse drug reactions in general practice, 177
MORLEY J. *see* CROWTHER S.D.
MORNEX J-F. *see* BOULIEU R.
MORTON G.C.A. *see* LENNARD L.
MOSS J. *see* MACKIE A.E.
MUCKLOW J. *see* BOATH E.
MULCAHY F. *see* BARRY M.
MULLEN A.B., CARTER K.C. & GRANT M.H. Effect of drug treatment on hepatic cytochrome P450 and Uc b_5 levels in *Leishmania donovani* infected mice, 216P
MULLER-EHMSEN J., FRANK K., BRIXIUS K. & SCHWINGER R.H.G. Increase in force of contraction by activation of the Na^{2+}-Ca^{2+}-exchanger in human myocardium, 399
MUMFORD J.P. *see* RICHENS A.
MURDAY A. *see* KNOTT C.
MUSCARA M.N. *see* PEDRAZZOLI JUNIOR J.

NA-BANGCHANG, CONGPUONG K., SIRICHAISINTHOP J., SUPRAKORB K. & KARBWANG J. Compliance with a 2 day course of artemether-mefloquine in an area of highly multi-drug resistant *Plasmodium falciparum* malaria, 639
NAISBITT D.J., O'NEILL P.M., PIRMOHAMED M. & PARK B.K. Disposition and toxicity of antimalarial agents in human neutrophils: implications for drug safety, 548P
NAKAMURA K. *see* IEIRI I.
NAKANO S. *see* IEIRI I.
NAKASHIMA M. *see* KOSUGE K.
NAKASHIMA M. *see* UMEMURA K.
NANKIVELL B.J. *see* SPICER S.T.
NAVARATNAM V. *see* MORDI M.N.
NEDELKA G. *see* POLLER U.D.
NEHMIZ G. *see* BOULTON-JONES J.M.
NEPVEUX P. *see* LAMRANI A.
NEUMANN J. *see* LAER S.
NEUPERT W. *see* OELKERS R.
NEUVONEN P.J. *see* LAINE K.
NEUVONEN P.J. *see* VILLIKKA K.
NEWBY D.E., SCIBERRAS D.G., MENDEL C.M., GERTZ B.J., BOON N.A. & WEBB D.J. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability, 493
NIALS A.T. *see* WEERSINK E.J.M.
NICHOLLS D.P. *see* McDOWELL G.
NICHOLS A.I. *see* BEERAHEE A.
NIGROVIC V., BANOUB A., DIEFENBACH C., MELLINGHOFF H. & BUZELLO W. Onset of the neuromuscular block simulated in an anatomical model, 55
NISHIMOTO M. *see* KOSUGE K.
NIXON A. *see* LYONS D.
NOLAN P.J. *see* WILLIAMSON B.H.
NOON J.P., BENNETT T. & COCKCROFT J.R. Adrenomedullin produced dilatation in human dorsal hand veins, 526P
NOORMOHAMED F.H., YOULE M.S., HIGGS C.J., GAZZARD B.G. & LANT A.F. Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment, 112
NORLEN B.J. *see* RANE A.
NORRIS L. *see* WEN Y.
NOTARIANNI L.J. *see* TURNER C.L.
NUGENT A.G. *see* McAULEY D.
NUGENT A.G. *see* McGURK C.
NUGENT A.G., McGURK C., McAULEY D., MAGUIRE S., SILKE B. & JOHNSTON G.D. The role of nitric oxide in reactive hyperaemia in the human forearm, 538P

O'CALLAGHAN G. & MINERS J. Paracetamol (acetaminophen): A Critical Bibliographic Review by L.F. Prescott, 124
O'CONNELL P.J. *see* SPICER S.T.
O'NEILL P.M. *see* NAISBITT D.J.
O'SHEA D., KIM R.B. & WILKINSON G.R. Modulation of CYP2E1 activity by isoniazid in rapid and slow *N*-acetylators, 99
OBORNE C.A., BATTY G.M., MASKREY V., SWIFT C.G. & JACKSON S.H.D. Development of prescribing indicators for elderly medical inpatients, 91
OELKERS R., NEUPERT W., WILLIAMS K.M., BRUNE K. & GEISSLINGER G. Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid, 145
OHASHI K. *see* KOSUGE K.
OLAH T. *see* SCIBERRAS D.G.
OLSEN M.H. *see* OLSEN N.V.
OLSEN N.V., OLSEN M.H., BONDE J., KANSTRUP I-L., PLUM I,, STRANGAARD S. & LEYSSAC P.P. Dopamine natriuresis in salt-repleted, water-loaded humans: a dose response study, 509
ON N. *see* SEABER E.
OULID-AISSA D. *see* BEHAR A.

PAGE C.P. *see* CROWTHER S.D.
PAINTAUD G. *see* WAKELKAMP M.
PALMER J.L., MITCHELL C., VEYRAT-FOLLET C. & FORSTER E.R. An assessment of the time to onset of anti-emetic activity from the ondansetron suppository in the ipecacuanha model of emesis, 551P
PARK B.K. *see* NAISBITT D.J.
PARK B.K. *see* POWELL H.
PARK B.K. *see* TOMLINSON E.S.
PARK B.K. *see* WILLIAMS D.P.

PARKER A.C., PRITCHARD P., PRESTON T., DALZELL A.M. & CHOONARA I. Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test, 467
PARKER T.J., DALEY-YATES P.T. & WOOD S.A. A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma, 589
PARRY-BILLINGS M. *see* HINDLE M.
PATAT A., TROCHERIE S., DURRIEU G., CIMAROSTI I., ALLAIN H., GANDON J.M. & ROSENZWEIG P. Effects of befloxatone on EEG and cognitive functions in elderly subjects, 552P
PAULSON J. *see* THORSSON L.
PECK R.W. *see* DIXON R.
PECK R.W. *see* SEABER E.
PEDRAZZOLI JUNIOR J., DE ALMEIDA PIEROSSI M., MUSCARA M.N., DIAS H.B., FERREIRA DA SILCA C.M., DUARTE MENDES F. & DE NUCCI G. Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers, 104
PEERS E.M. *see* HINDLE M.
PENG S.-W., FINNSTROM N., EDWARDS R.J., BOOBIS A.R. & RANE A. Cytochrome p450 in fetal tissues, as assessed by mRNA quantitation and protein expression, 217P
PENSTON J.G. & McCOLL K.E.L. Eradication of *Helicobacter pylori*: an objective assessment of current therapies, 223
PERUCCA F. *see* SPINA E.
PETERSON D.W. *see* CHARLETT A.
PETERSON D.W. *see* PURKISS A.G.
PETIT M.J., BHABRA M.J., JONES M., KINGSWOOD J.C. & SHARPSTONE P. The bioavailability of stored epoetin beta in volunteer dialysis patients, 545P
PEUCH A.J. *see* BERLIN I.
PFAFFERNDORF M. *see* BAAN J.
PIOTROVSKIJ V. *see* SNOECK E.
PIRMOHAMED M. *see* NAISBITT D.J.
PIRMOHAMED M. *see* POWELL H.
PIRMOHAMED M. *see* WILLIAMS, D.P.
PLANE F. *see* LEWIS C.
PLUM I, *see* OLSEN N.V.
POHJALAINEN T., GEJMAN P.V., RINNE J., MAGREN K., SYVALAHTI E. & HIETALA J. The human D_2 receptor: relationship between exonic gene variants and receptor binding characteristics *in vivo*, 213P
POIRIER J.-M. *see* CHEYMOL G.
POLLER U.D., NEDELKA G., FUCHS B., RADKE J. & BRODDE O.-E. The M1-cholinoreceptor antagonist pirenzepine causes, in low doses, negative chronotropic effects in healthy volunteers, 529P
POLVINO W.G. *see* SCIBERRAS D.G.
POSNER J. *see* DIXON R.
POSNER J. *see* HUSSEIN Z.
POSNER J. *see* SEABER E.
POSNER J. *see* WOOTTON R.
POSTMAN D.S. *see* WEERSINK E.J.M.
POWELL H., KITTERINGHAM N.R., PIRMOHAMED M., SMITH D.A. & PARK B.K. CYP2E1: Evaluation of the relationship between genotype and phenotype using a human liver bank, 547P
POWELL R.J. *see* GARDNER-MEDWIN J.M.
PRESTON T. *see* PARKER A.C.
PRICHARD B.N.C. *see* ALARAYYED N.A.
PRITCHARD M.P., BLAKE J.A.R., FRIEDBERG T., BURCHELL B. & WOLF C.R. Generation of functional human monooxygenase system in *Escherichia coli*, 210P
PRITCHARD P. *see* PARKER A.C.
PUJADE-LAURAINE E. *see* BEHAR A.
PURKISS A.G. *see* CHARLETT A.
PURKISS A.G., CHARLETT A., PETERSON D.W., WELLER C., DOBBS S.M. & DOBBS R.J. Serum concentration of interleukin-6 in sufferers from idiopathic parkinsonism and controls, 554P

RADAT F. *see* BERLIN I.
RADKE J. *see* POLLER U.D.
RAMSAY L.E. *see* GHARAMANI P.
RANE A. *see* FINNSTROM N.
RANE A. *see* PENG S.-W.
RANE A., SODERSTROM T., BREKKAN E., NORLEN B.J., UNGE T., ANDERSSON S. & BJELFMAN C. Gene expression of target enzyme for intervention therapy in prostatic disease, 218P
RANSTAM J. *see* MERLO J.
RASCOL O. *see* TAYLOR A.C.
REED J. *see* SCIBERRAS D.G.
REQUEJO A.A. *see* MORIDE Y.
RICHENS A., McEWAN J.R., DEYBACJ J.C. & MUMFORD J.P. Evidence for both *in vivo* and *in vitro* interaction between vigabatrin and alanine transaminase, 163
RILEY R.J. *see* SLEE D.
RINNE J. *see* POHJALAINEN T.
RITTER J.M. *see* BRETT S.E.
RITTER J.M. *see* STRATTON P.D.
RITTER M. *see* SANDWALL P.
RODRIGO C. *see* SEMPERE J.M.
ROLAN P.E. *see* SEABER E.
ROLAN P.E. *see* WOOTTON R.
ROSENZWEIG P. *see* PATAT A.
ROSTAMI-HODJEGAN A., LENNARD M.S. & TUCKER G.T. Kinetic analysis of *in vitro* drug metabolism data: a literature survey, 544P
ROUTLEDGE P.A. *see* AL-SHAREEF A.
ROUTLEDGE P.A. *see* BUSS D.C.
ROWLAND-YEO K. *see* GHARAMANI P.
RYDBERG T., JONSSON A., KARLSSON M.O. & MELANDER A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics, 373

SABROE R.A., KENNEDY C.T.C. & ARCHER C.B. The effects of topical doxepin cream and oral terfenadine on the cutaneous responses to histamine and substance P in human skin, 530P
SANDWALL P., LO M-W., DAHLEN P., FURTEK C., RITTER M., JONZON B., TYBRING G., LIND M., McCREA J. & ALVAN G. The metabolism of losartan to the active metabolite E-3174 in subjects who are extensive and poor metabolizers of debrisoquine (CYP2D6) or mephenyton (CYP2C19), 215
SAUNDERS D.A., BEGG E.J., KIRKPATRICK C.M.J., YEO J., GRAHAM G.G. & BAILEY R.R. Measurement of total phospholipids in urine of patients treated with gentamicin, 435
SAWYER A. *see* SHARMA S.
SCATINA J. *see* BALL S.E.
SCHAGERS R.F. *see* TAGUCHI K.
SCHMETTERER L. *see* KREJCY K.
SCHOEMAKER R.C. *see* FAAIJ R.A.
SCHOLZ H. *see* LAER S.
SCHUTZ W. *see* KREJCY K.
SCHWINGER R.H.G. *see* MULLER-EHMSEN J.
SCIBERRAS D.G. *see* NEWBY D.E.
SCIBERRAS D.G., MAJMUDAR N., BOWMAN A.J., MASSEY A., BARDSTREET T., CLAYTON R., REED J., SHADLE C., GOLDBERG M.R. & FORD G.A. A study of the effects of MK-462 (rizatriptan), clonidine and sumatriptan on autonomic function, 535P
SCIBERRAS D.G., POLVINO W.G., GERTZ B.J., CHENG H., STEPANAVAGE M., WITTREICH J., OLAH T., EDWARDS M. & MANT T. Initial human experience with MK-462 (rizatriptan): a novel 5-HT_{1D} agonist, 49
SCORDO M.G. *see* SPINA E.
SEABER E., ON N., DIXON R.M., GIBBENS M., LEAVENS W.J., CHITTICK G., POSNER J., ROLAN P.E. & PECK R.W. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90), 579
SEMPERE J.M., RODRIGO C., CAMPOS A., VILLALBA J.F. & DIAZ J. Effect of Anapsos (*Polypodium leucotomos* extract) on *in vitro* production of cytokines, 85
SHADLE C. *see* SCIBERRAS D.G.
SHAH D. *see* KNOTT C.
SHARMA S., SAWYER A., WILLIAMS

A. & FORSLING M.L. The effect of acute melatonin administration on the oxytocin response to increased plasma osmolality in man, 532P
SHARPSTONE P. *see* PETIT M.J.
SHAW C. *see* McDOWELL G.
SHEDLOFSKY S.I., ISRAEL B.C., TOSHEVA R. & BLOUIN R.A. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women, 627
SHEMOUDA G. *see* DUCHARME J.
SHETTY H.G.M. *see* AL-SHAREEF A.
SHINE D. & McDONALD J. A computer model for the measurement of compliance using a dual tracer technique, 283
SILKE B. *see* NUGENT A.G.
SIRICHAISINTHOP J. *see* NA-BANGCHANG
SKELLERN G.G. *see* TETTEY J.
SLEE D., HOWBROOK D.N., BANDERA M., FRIEDBERG T., LOGAN C.J. & RILEY R.J. Kinetic analysis of heterologously expressed CYP2D6 and comparison with the human liver microsomal enzyme, 549P
SMITH C.C.T. *see* ALARAYYED N.A.
SMITH D.A. *see* POWELL H.
SMITH J. *see* LYONS D.
SNOECK E. *see* CHEYMOL G.
SNOECK E. *see* KAMALI F.
SNOECK E., PIOTROVSKIJ V., VAN PEER A., DANHOF M., VER DONCK K., WOESTENBORGHS R., VAN BELLE H., VAN BORTEL L., VAN GOOL R., DUPONT A.G. & HEYKANTS J. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates, 603
SODERSTROM T. *see* RANE A.
SOGNI P. *see* LAMRANI A.
SOMCHIT N., WADE L.T., GARDNER I.B., KENNA J.G. & CALDWELL J. Immunochemical identification of modified hepatic protein adducts which could be involved in the hepatotoxicity of diclofenac, 208P
SOMOGYI A.A. *see* COLLER J.K.
SOUL-LAWTON J. *see* WOOTTON R.
SPICER S.T., LIDDLE C., CHAPMAN J.R., BARCLAY P., NANKIVELL B.J., THOMAS P. & O'CONNELL P.J. The mechanism of cyclosporine toxicity induced by clarithromycin, 194
SPINA E., AVENOSO A., CAMPO G.M., SCORDO M.G., CAPUTI A.P. & PERUCCA F. Effect of ketoconazole and desipramine in healthy subjects, 315
SPREUX-VAROQUAX O. *see* BERLIN I.
SRIVASTAVA N. *see* FAAIJ R.A.
STEER J.H., VOUNG Q. & JOYCE D.A. Suppression of human monocyte tumour necrosis factor-release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression, 383
STEPANAVAGE M. *see* SCIBERRAS D.G.
STOTT R.R. *see* GOLDING J.F.
STRANGAARD S. *see* OLSEN N.V.
STRANGE P.G. *see* VILE J.M.
STRATTON P.D. & RITTER J.M. The influence of gender on the rate of volume increase of platelets exposed to weak acid from patients with essential hypertension, 527P
STRICKER B.H. *see* GARCIA-RODRIGUEZ L.A.
STRUTHERS A.D. *see* LEE A.F.C.
STRUTHERS A.D. *see* McDOWELL G.
SUISSA S. *see* ERNST P.
SUPRAKORB K. *see* NA-BANGCHANG
SWIFT C.G. *see* OBORNE C.A.
SYVALAHTI E. *see* POHJALAINEN T.
SZABADI E. *see* BITSIOS P.

TAGUCHI K., SCHAGERS R.F. & MICHEL M.C. Development of a radioreceptor assay for human α-adrenoceptor subtypes: application to tamsulosin and terazaosin pharmacokinetics, 546P
TAHVANAINEN K. *see* JARRTI T.
TAKANUKI F. *see* AOYAMA K.
TASHIRO N. *see* IEIRI I.
TAVERNOR S. *see* BITSIOS P.
TAYLOR A.C. *see* BEERAHEE A.
TAYLOR A.C., CYRONAK M., CITERONE D.R., FITZPATRICK K., COOPER S., LOPEZ-GILL A. & RASCOL O. Lack of pharmacokinetic interaction between ropinirole and theophylline in parkinsonian patients, 555P
TAYLOR J.Y. *see* GARDNER-MEDWIN J.M.
TENERO D. *see* MARTIN D.E.
TESTA B. *see* CHEYMOL G.
TETTEY J., GRANT M.H., MIDGLEY J.M., SKELLERN G.G. & WILKINSON R. Uptake and metabolism of ethidium bromide by rat hepatocytes, 215P
THOMAS M. *see* KELLY T.B.
THOMAS P. *see* SPICER S.T.
THOMAS S.H.L. & BATEMAN D.N. Appropriateness of use of gastric decontamination procedures in poisoned patients, 527P
THOMAS S.H.L. & BATEMAN D.N. Paracetamol poisoning in the North East of England, 546P
THOMAS S.H.L. *see* KAMALI F.
THOMPSON P.J. *see* WILLIAMSON B.H.
THON M. *see* FINNSTROM N.
THORSSON L., DAHLSTROM K., EDSBACKER S., KALLEN A., PAULSON J. & WIREN J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects, 155
THURMANN P.A. *see* HARDER S.
TIPPINS J.R. *see* KNOTT C.
TJIA J. *see* BARRY M.
TOMLINSON E.S., LEWIS D.F.V., MAGGS J.L., PARK B.K. & BACK D.J. Dexamethasone metabolism by human liver and kidney *in vitro* and use of putative molecular models of CYP17 and CYP3A4, 549P
TOMPSON D. *see* MARTIN D.E.
TOSHEVA R. *see* SHEDLOFSKY S.I.
TOYOKI T. *see* AOYAMA K.
TREACHER D.F. *see* KOSTOGLOU-ATHANASSIOU I.
TRIBE A.E. *see* WILLIAMSON B.H.
TROCHERIE S. *see* PATAT A.
TUCKER G.T. *see* BACK D.J.
TUCKER G.T. *see* GHAHRAMANI P.
TUCKER G.T. *see* ROSTAMI-HODJEGAN A.
TURCK D. *see* BOULTON-JONES J.M.
TURNER C.L., WILSON A., AHMED A., JONES R.W. & NOTARIANNI L.J. Plasma antioxidant status: age and gender differences, 534P
TYBRING G. *see* SANDWALL P.

UCHIDA T. *see* AOYAMA K.
UMEMURA K. *see* KOSUGE K.
UMEMURA K., KONDO K., IKEDA Y., URATA Y. & NAKASHIMA M. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers, 613
UNGE T. *see* RANE A.
URAE A. *see* IEIRI I.
URATA Y. *see* UMEMURA K.

V.D. MEULEN J. *see* CLEOPHAS T.J.M.
VALENTE L. *see* BIRKETT D.J.
VALIMAKI I. *see* JARRTI T.
VAN BELLE H. *see* SNOECK E.
VAN BORTEL L. *see* SNOECK E.
VAN GOOL R. *see* SNOECK E.
VAN GRIENSVEN J.M.TH. *see* FAAIJ R.A.
VAN PEER A. *see* LEFEBVRE R.A.
VAN PEER A. *see* SNOECK E.
VAN ZWIETEN P.A. *see* BAAN J.
VANTO T. *see* JARRTI T.
VENTRESCA G.P. *see* MACKIE A.E.
VER DONCK K. *see* SNOECK E.
VERMEIJ P. *see* BAAN J.
VEYRAT-FOLLET C. *see* PALMER J.L.
VIDON N. *see* LAMRANI A.
VILE J.M., McKINNELL I., FITZKE F.W., WESTCOFF M., DONNELLY N., BAMBER R.W.K. & STRANGE P.G. Effects of antipsychotic medication of visual function in schizophrenic patients, 553P
VILLALBA J.F. *see* SEMPERE J.M.
VILLIKKA K., KIVISTO K.T., LAMBERG T.S., KANTOLA T. & NEUVONEN P.J. Concentrations and effects of zoplicone are greatly reduced by rifampicin, 471
VUONG Q. *see* STEER J.H.

WADA Y. *see* IEIRI I.
WADE L.T. *see* SOMCHIT N.
WAINER I.W. *see* DUCHARME J.

WAKELKAMP M., ALVAN G. & PAINTAUD G. Natriuretic efficiency of frusemide as a consequence of drug input rate, 481
WALD MEYERS M. & JICK H. Hospitalization for serious blood and skin disorders following use of co-trimoxazole, 446
WALKER R.J. *see* ZHANG H.
WALLANDER M-A. *see* GARCIA-RODRIGUEZ L.A.
WALLER P.C. *see* EVANS S.J.W.
WALLEY T. & HAYCOX A. Pharmacoeconomics: basic concepts and terminology, 343
WALLEY T. Meeting report. VI World Congress on Clinical Pharmacology and Therapeutics, Buenos Aires, 4–9 August 1996, 21
WALLEY T. *see* HAYCOX A.
WALLEY T. *see* LLOYD-JONES G.
WANWIMOLRUK S. *see* ZHANG H.
WATANABE T. *see* AOYAMA K.
WEBB D.J. *see* NEWBY D.E.
WEBSTER J. *see* LYONS D.
WEERSINK E.J.M., POSTMAN D.S., KOETER G.H., MAN Y., NIALS A.T. & COLEMAN R.A. Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics, 169
WEISSENBURGER J. *see* CHEYMOL G.
WELCH J. *see* LENNARD L.
WELLER C. *see* CHARLETT A.
WELLER C. *see* PURKISS A.G.
WELLS F. Fraud and misconduct in medical research, 3
WEN Y., DOYLE M.C.T., HARRISON R.F. & FEELY J. Oestrogen-containing hormone replacement therapy in postmenopausal women: anti- rather than pro-oxidant, 535P
WEN Y., KILLALEA S., McGETTIGAN P., HALL M., HEMERYCK L., NORRIS L., COOKE T. & FEELY J. Effect of vitamin E supplementation in hyperlipidaemic patients: comparison of *in vivo* and *in vitro* effects, 536P
WERNSDORFER W.H. *see* MORDI M.N.
WESTCOFF M. *see* VILE J.M.
WHEELER M.J. *see* KOSTOGLOU-ATHANASSIOU I.
WHITE M. & LEENAN F.H.H. Effects of age on cardiovascular responses to adrenaline in man, 407
WILDER-SMITH C.H. & BETTIGA A. The analgesic tramadol has minimal effect on gastrointestinal motor function, 71
WILKIN J.P. *see* KNOTT C.
WILKINSON G.R. *see* O'SHEA D.
WILKINSON R. *see* TETTEY J.
WILLIAMS A. *see* SHARMA S.
WILLIAMS D.P., PIRMOHAMED M. & PARK B.K. Demonstration of the cytotoxicity of the chemically reactive metabolite of clozapine using a novel *in vitro* assay, 550P
WILLIAMS K.M. *see* OELKERS R.
WILLIAMSON B.H., NOLAN P.J., TRIBE A.E. & THOMPSON P.J. A placebo-controlled study of flumazenil in bronchoscopic procedures, 77
WILSON A. *see* TURNER C.L.
WIRE P. *see* FALCOZ C.
WIREN J-E. *see* THORSSON L.
WITTREICH J. *see* SCIBERRAS D.G.
WOESTENBORGHS R. *see* LEFEBVRE R.A.
WOESTENBORGHS R. *see* SNOECK E.
WOLF C.R. *see* PRITCHARD M.P.
WOLTZT M. *see* KREJCY K.
WOOD N. *see* DINGEMANSE J.
WOOD S.A. *see* PARKER T.J.
WOOTTON R., SOUL-LAWTON J., ROLAN P.E., FOOK SHEUNG C.T.C., COOPER J.D.H. & POSNER J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers, 23

YEO J. *see* SAUNDERS D.A.
YEO W.W. *see* GHARAMANI P.
YOGENDRAN L. *see* ASTBURY S.
YOSHIOKA S. *see* IEIRI I.
YOULE M.S. *see* NOORMOHAMED F.H.
YOUNG M.M.R. *see* LYONS D.

ZEVIN S. *see* BENOWITZ N.L.
ZHANG H., COLVILLE P.F., WALKER R.J., MINERS J.O., BIRKETT D.J. & WANWIMOLRUK S. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine, 245

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings)

α-adrenoceptors, 301
α-adrenoceptor subtypes, 546P
Acetylcholine, 391
Acute intermittent porphyria, 339
Acute renal failure, 194
Adenosine breakdown inhibition, 603
Adrenoceptor responsiveness, 407
Adrenomedullin, 526P
Advanced cancer, 653
Adverse drug reactions, 117, 446, 649
Age, 534P, 553P
Ageing, 407
Airway hyperresponsiveness, 169
Alanine transaminase, 163
Allopurinol, 197
Aminoglycosides, 435
Amlodipine, 339
Angina pectoris, 333
Angiotensin II, 501, 526P, 661
Angiotensin II receptors, 301
Angiotensin converting enzyme activity, 212P
Angiotensin receptor antagonist, 323
Antacids, 269
Anti-epilepsy drugs, 163
Anti-migraine drugs, 429
Anti-ulcer drugs, 183, 449
Antibiotic prescribing, 449
Antibiotics, 223
Antibodies, 208P
Antiemetic, 551P
Antimalarials, 548P
Antioxidant status, 534P
Antipsychotic medication, 553P
Antipyrine, 627
Artemether, 363, 639
Arterial baroreflex, 407
Aspartate transaminase, 164
Astemizole, 319
Asthma, 9, 206P, 211P, 339, 541P, 542P
Atrial natriuretic peptide, 329
Audit, 556P
Autonomic function, 535P
Autonomic nervous system, 421

β_2-adrenoceptor antagonist, 169
β-adrenoceptor antagonist, 201
β-adrenoceptor blockers, 563
β-adrenoceptors, 9, 301
β_1-adrenoceptor selective blockade, 291
β_2-adrenoceptor activity, 529P
Bayesian, 125
(±)BDF 9148, 399
Befloxatone, 552P
Bioavailability, 259, 542P, 545P, 556P, 571, 579, 589, 593
Bioequivalence, 593
Blood, 189
Blood disorders, 446, 649
Blood pressure, 273
Blood pressure monitoring, 535P
Blood pressure variability, 421
Body frame size, 534P
Bone metabolism, 211P
Bradykinin, 543P
Brain natriuretic peptide, 329
Breath activated pressurized aerosol, 542P
Breath test, 194
Bronchial asthma, 421
Budesonide, 211P

CYP17, 549P
CYP1A2, 253
CYP2C19, 215P, 441, 659
CYP2C9, 441
CYP2D6, 210P, 215P, 315, 619
CYP2D6 m RNA, 210P
CYP2D6, heteologously expressed, 549P
CYP2E1, 547P
CYP3A, 19, 245
CYP3A4, 210P, 315, 549P
Caffeine, 197, 467
Caffeine breath test, 467
Caffeine metabolic ratios, 253
Calcium mobilization, 415
Candidate genes, 521
Candoxatril, 329
Cardiac glycosides, 399
Cardiovascular disease, 521, 523
Carteolol, 9
Celiprolol, 9
Cerebral blood flow, 501
Children, 467
Chlorpromazine, 532P
Cholinesterase activity, 513
Cigarette, 259
Cigarette smoke, 211P
Cimetidine, 183, 201, 467
Ciprofloxacin, 545P
Clarithromycin, 194
Clinical pharmacology, 15
Clinical trials, 219, 559
Clonidine, 535P
Co-trimoxazole, 446, 649
Cognitive function, 552P
Compliance, 283, 639
Computerized dose prediction, 125
Continuing medical education, 643
Contractile function, 537P
Control group, 219
Core curriculum, 15
Coriolis, 633
Coronary heart disease, 206P
Corticosteroid, 653
Corticotropin releasing factor, 206P
Cortisol, 383, 543P
Cortisol suppression, 155
Cotinine, 259
Course development, 643
Creatinine, 435
Curriculum development, 15
Cyclooxygenase inhibition, 539P, 540P
Cyclosporine A, 194, 340
Cytochrome P450, 194, 217P, 627
Cytochrome P450 2E1, 209P

Debrisoquine, 215P
Delphi, 643
Depression, 532P
Dermal microcirculation, 391
Desipramine, 315
Dexamethasone, 549P
Diabetes mellitus, 373
Diabetics, non-insulin dependent, 538P, 539P
Dialysis patients, 545P
Diclofenac, 208P
Digit symbol substitution test, 214P
Digoxin, 283, 475, 661
Diltiazem, 367
Diskhaler, 155, 540P, 541P
Diskus, 540P, 541P
Disposition, 548P
Distance learning, 643
Distribution, 563
Diuretics, 309
Docetaxel, 653
Dopamine, 509
Dopamine D_2 receptor, 213P
Doppler sonography, 501
Dorsal hand vein, 526P
Dose response, 509
Doxazoin, 339, 415
Doxepin, 530P
Draflazine, 603
Drug interaction, 315, 319, 367, 661
Drug metabolism, 245, 544P, 627
Drug safety, 548P
Dry powder inhaler, 336, 530P
Dry powder inhaler device, 542P

EEG, 552P
ELISA, 571
Efficiency, 481
Elbow width, 534P
Elderly, 552P
Enantiomer, 145, 169, 355
Endothelin, 539P, 540P
Endothelium, 537P
Endotoxin, 627
Enzyme induction, 471
Epilepsy, 457
Epoetin, 545P
Eprosartan, 661
Erythromycin, 194
Escherichia coli, 210P
Ethidium bromide, 215P
Ethnic variation, 521
Exercise, 9
Extensive metabolizer, 215P

Fat metabolism, 291
Felodipine, 535P
Female sex hormones, 212P
Females, 189
Fenbufen, 545P
Fenoterol, 9
Fetal tissues, 217P
Fluid retention, 653

© 1997 Blackwell Science Ltd

Fluoxetine, 619
Flurbiprofen, 145
Fluticasone, 211P
Fluticasone propionate, 155, 540P, 541P
Fluvoxamine, 619
Forearm plethysmography, 493
Forearm vasculature, 538P
Fraud, 3
Frusemide, 481
Fundus pulsations, 501

GABA aminotransferase, 163
GR117289C, 323
Gastric decontamination, 527P
Gender, 407, 527P, 534P, 579, 627
Gene expression, 218P
General practice, 643
Genetics, 521
Genotype, 547P
Gentamicin, 125, 435
Glibenclamide, 373
Glucose, 373
Glutathione transferase pi immunoreactivity, 213P
Growth hormone, 543P

Haemodynamics, 407
Halothane, 209P
Heart rate, 633
Heart rate variability, 421
Helicobacter pylori, 223
Hepatic antigens, 208P
Hepatic protein adducts, 208P
Hepatocytes, 215P
Hepatotoxicity, 208P
Hexobarbitone, 627
Histamine, 530P, 593
Histamine H_2-receptor antagonists, 201
Hormone replacement therapy, 535P
Hospital prescribing, 556P
Human, 383
Human coronary arteries, 213P
Human liver microsomes, 245, 619
Human myocardium, 399
Hydroxycotinine, 259
5-hydroxytryptamine, 327
Hyoscine, 633
Hyperlipidaemic patients, 536P
Hypertension, 339, 521, 527P
Hypoxaemia, 309

Idiopathic parkinsonism, 554P
Imipramine, 315
Imipril, 475
Immunoprecipitation, 208P
Inflammation, 627
Inhibition, 467
Interaction, 163, 269, 471, 545P, 555P
Interleukin-6, 554P
Intramuscular, 593
Intravenous, 571
Intrinsic clearance, 659
Ionopheresis, 391
Ipecacuanha, 551P
Ischaemic heart disease, 521, 522
Isomers, 529P
Isosorbide mononitrate, 333
Itraconazole, 319

JTP-4819, 613

Ketoconazole, 315
Kidney function, 509
Kinetic analysis, 544P
Kinetics, 259

L-arginine, 528P
Lamotrigine, 457
Laser Doppler fluximetry, 391
Leishmania donovani, 216P
Lipid lowering drugs, 206P
Lipid-lowering drugs, 291
Lipids, 212P
Lipophilicity, 563
Lithium clearance, 509
Liver, 183
Liver microsomes, 209P
Liver needle biopsies, 217P
Lorazepam, 532P
Losartan, 215P

M_1-cholinoceptor antagonist, 529P
MPTP, 210P
Malaria, 363
Mathematical modelling, 283
Medical research, 3
Meeting report: Genetics and the Therapy of Cardiovascular disease, 521
Melatonin, 532P, 543P
Melfloquine, 639, 665
Mephenytoin, 215P
Mercaptopurine, 544P
Meta-analysis, 349
Metabolic ratio, 659
Metabolism, 189, 259, 579
Metabolites, 373
Metered dose inhaler, 336, 530P
Methylprednisolone, 589, 593
Methylprednisolone succinate, 589
Methylprednisolone suleptanate, 589
7-methylxanthine, 197
Metoprolol, 535P
Moclobemide, 532P, 551P
Modelling, 593
Monoamine oxidase inhibition, 532P
Monocytopaenia, 383
Monotherapy, 457
Motion sickness, 633
mRNA quantitation, 217P
Multiarray diagonal gel electrophoresis, 521
Multidrug resistance, 639
Multiple dosing, 273
Muscarinic receptors, 633
Mutant alleles, 659
Mydriasis, 551P

N-dealkylation, 137
NONMEM, 457
Na^+-channel activators, 399
Naftopidil, 415
Nasal spray, 259
Natriuresis, 509
Natriuretic effect, 481
Nebivolol, 201
Nephrotoxicity, 435
Neuropeptides, 613
Neutral endopeptidase inhibitor, 329
Nicotine, 211P, 259
Nifedipine, 514
Nitric oxide, 538P
Nitric oxide synthase, 522, 528P
Non-insulin dependents, 373
Non-linear red blood cell partioning, 603
Nonselective β-adrenoceptor blockade, 301
Nonsteroidal antiinflammatory drugs, 145
Nucleodise transport inhibitor, 603

Obese subjects, 563
Ocular blood flow, 501
Ocular safety, 449
Oestrogen, 523
Omeprazole, 441, 449
Once daily sustained release formulation, 333
Ondansetron, 551P
Oxypurinol, 197
Oxytocin, 532P

Paracetamol, 546P
Parkinson's disease, 210P, 255P, 556P
Parkinsonism, 553P
Paroxetine, 619
Partial agonist, 9
Pentosan polysulphate sodium, 556P
Perceived exertion, 291
Pharmaceutical industry, 523
Pharmacodynamic modelling, 373
Pharmacodynamics, 145, 197, 269, 373, 383, 481, 493, 545P, 593, 603
Pharmacoeconomics, 343, 451P, 559
Pharmacoepidemiology, 429
Pharmacokinetic-dynamic interaction, 475
Pharmacokinetics, 145, 269, 273, 355, 363, 367, 373, 383, 457, 471, 531P, 535P, 540P, 541P, 544P, 546P, 555P, 556P, 563, 571, 579, 603, 661
Pharmacovigilance, 177
Phenobarbitone, 283
Phenotype, 547P
Phenytoin, 441
Phospholipids, 435
Picumeterol, 169
Pirenzapine, 529P
Placebo, 219
Plasma ammonia, 291
Plasma lactate, 291
Plasma profile, 333
Plasmodium falciparum, 639
Platelets, 415, 527P
Poisoning, 527P, 546P
Poor metabolizer, 215P
Population, 457
Population analysis, 603
Population pharmacokinetics, 589
Positive inotropic agents, 399
Positron emission tomography, 211P
Postmenapausal women, 535P
Potassium ATP channel, 537P
Prednisolone, 383
Premedication, 653
Prescribing, 449
Prescription data, 429
Probenecid, 481
Proguanil, 659
Prolactin, 543P
Prolyl endopeptidiase inhibitor, 613
Promedrol, 593
Prostaglandins, 145
Prostatic disease, 218P
Protein binding, 207P
Protein expression, 217P

Protocol evaluation, 533P
Proton pump inhibitor, 223
Pulmonary circulation, 309

Quinine, 245

Radiolabel, 579
Radioreceptor assay, 546P
Randomized controlled trial, 349
Ranitidine, 201
Reactive hyperaemia, 538P
Receptor antagonist, 661
Receptor binding, 213P
Recombinant human interleukin-11, 571
Red blood cell occupancy, 603
Renal haemodynamics, 509
Renal transplant patients, 340
Renin-angiotensin system, 309
Renin-angiotensin system genes, 522
Reproducibility, 493
Rhabdomyolysis, 194
Rifampicin, 471
Ritonovir, 531P
Rizatriptan, 535P
Ropinirole, 555P, 556P

Saccadic distractability, 532P
Salbutamol, 9, 336, 421, 529P, 530P, 542P
Salmeterol, 9
Saphenous vein, 537P
Saquinovir, 531P
Schizophrenia, 553P
Selegiline, 551P
Sertraline, 619
Simvastatin, 194
Skin, 530P
Skin conductance, 633
Skin disorders, 649
Sodium, 509
Sodium stibogluconate, 216P
Solu-medrol, 594
Sotalol, 269
Spontaneous reporting, 177
Stereoselective hydroxylation, 441
Stevens-Johnson syndrome, 446, 649
Subcutaneous, 571
Substance P, 493, 530P
Succinate, 593
Suction blister, 145
Suleptanate, 593
Sulphonylurea, 373
Sumatriptan, 327, 429, 535P
Systemic availability, 155

TNF-alpha, 383
Tamoxifen, 189
Tamsulosin, 546P
Terazosin, 546P
Terbinafine, 340
Terfenedine, 530P
Theophylline, 555P, 627
Theophylline metabolic ratios, 253
Therapeutics, 643
Thiopentone, 355
311C90, 273, 579
Tobramicin, 125
Tolerability, 493
Toxic epidermal necrolysis, 446, 649
Toxicity, 548P
Transdermal, 259
Triazolam, 367
Tricyclic antidepressants, 619
Tubular function, 509
Tumour necrosis factor α, 553P

Variability, 145
Vasoconstriction, 327
Vasodilation, 493
Venlafaxine, 619
Vigabatrin, 163
Visual function, 553P
Vitamin E, 536P
Volunteers, 273

Xanthine oxidase, 197

Zolmitriptan, 273, 579
Zoplicone, 471